Biocon is all set to raise up to Rs 4,500 crore through a qualified institutions placement (QIP) and has set the floor price of Rs 340.20 per Equity Share. Subsequent to approval from shareholders and board of directors, the Fund Raising Committee of the company at its meeting held on June 16, 2025 authorised the opening of the issue (qualified institutions placement).
Earlier in April 2025, the company’s board had approved raising of funds by way of issuance any instrument or security, including equity shares, non-convertible debt instruments along with warrants, any other convertible securities or any other eligible securities any combination thereof, by way of qualified institutions placement(s), rights issue, preferential allotment or private placement(s) and/or any combination thereof, for an aggregate amount of up to Rs 4,500 crore, in one or more tranches and/or one or more issuances.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
